Skip to content
10-Q

Quarterly Report

Adverum Biotechnologies, Inc.

0001628280-25-051593

← back to feed
Filed
Nov 12, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Nov 7, 2025 22.08M sh
Shares Diluted Q3 2025 · Sep 30, 2025 23.49M sh
Shares Diluted Q3 2025 · Sep 30, 2025 21.82M sh
Shares Diluted Q3 2025 · Sep 30, 2024 20.88M sh
Shares Diluted Q3 2025 · Sep 30, 2024 19.41M sh
Capex Q3 2025 · Sep 30, 2025 $482K
Capex Q3 2025 · Sep 30, 2024 $327K
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$109.65M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$64.21M
Short Term Investments Q3 2025 · Sep 30, 2025 $0
Short Term Investments Q3 2025 · Dec 31, 2024 $65.04M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $26.06M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $60.65M
Cash And Equivalents Q3 2025 · Sep 30, 2024 $92.85M
Stockholders Equity Q3 2025 · Sep 30, 2025 −$55.65M
Stockholders Equity Q3 2025 · Jun 30, 2025 −$20.22M
Stockholders Equity Q3 2025 · Mar 31, 2025 $26.42M
Stockholders Equity Q3 2025 · Dec 31, 2024 $70.71M
Stockholders Equity restated Q3 2025 · Sep 30, 2024 $108.27M
Stockholders Equity restated Q3 2025 · Jun 30, 2024 $137.4M
Stockholders Equity restated Q3 2025 · Mar 31, 2024 $163.68M
Stockholders Equity restated Q3 2025 · Dec 31, 2023 $67.22M
Current Liabilities Q3 2025 · Sep 30, 2025 $44.75M
Current Liabilities Q3 2025 · Dec 31, 2024 $22.9M
Total Liabilities Q3 2025 · Sep 30, 2025 $128.05M
Total Liabilities Q3 2025 · Dec 31, 2024 $109.13M
Current Assets Q3 2025 · Sep 30, 2025 $28.91M
Current Assets Q3 2025 · Dec 31, 2024 $131.3M
Total Assets Q3 2025 · Sep 30, 2025 $72.4M
Total Assets Q3 2025 · Dec 31, 2024 $179.84M
Eps Diluted Q3 2025 · Sep 30, 2025 −$2.03
Eps Diluted Q3 2025 · Sep 30, 2025 −$6.59
Eps Diluted restated Q3 2025 · Sep 30, 2024 −$1.55
Eps Diluted restated Q3 2025 · Sep 30, 2024 −$4.64
Eps Basic Q3 2025 · Sep 30, 2025 −$2.03
Eps Basic Q3 2025 · Sep 30, 2025 −$6.59
Eps Basic restated Q3 2025 · Sep 30, 2024 −$1.55
Eps Basic restated Q3 2025 · Sep 30, 2024 −$4.64
Sga Expense Q3 2025 · Sep 30, 2025 $9.11M
Sga Expense Q3 2025 · Sep 30, 2025 $41.31M
Sga Expense restated Q3 2025 · Sep 30, 2024 $15M
Sga Expense restated Q3 2025 · Sep 30, 2024 $44.6M
Rd Expense Q3 2025 · Sep 30, 2025 $38.91M
Rd Expense Q3 2025 · Sep 30, 2025 $104.79M
Rd Expense Q3 2025 · Sep 30, 2024 $20.44M
Rd Expense Q3 2025 · Sep 30, 2024 $52.95M
Net Income Q3 2025 · Sep 30, 2025 −$47.65M
Net Income Q3 2025 · Sep 30, 2025 −$143.86M
Net Income Q3 2025 · Jun 30, 2025 −$49.19M
Net Income Q3 2025 · Mar 31, 2025 −$47.02M
Net Income restated Q3 2025 · Sep 30, 2024 −$32.35M
Net Income restated Q3 2025 · Sep 30, 2024 −$90M
Net Income restated Q3 2025 · Jun 30, 2024 −$30.5M
Net Income restated Q3 2025 · Mar 31, 2024 −$27.15M
Operating Income Q3 2025 · Sep 30, 2025 −$48.02M
Operating Income Q3 2025 · Sep 30, 2025 −$146.1M
Operating Income restated Q3 2025 · Sep 30, 2024 −$34.44M
Operating Income restated Q3 2025 · Sep 30, 2024 −$96.54M
Revenue Q3 2025 · Sep 30, 2025 $0
Revenue Q3 2025 · Sep 30, 2025 $0
Revenue Q3 2025 · Sep 30, 2024 $1M
Revenue Q3 2025 · Sep 30, 2024 $1M